Type I interferon signaling regulates activation of the absent in melanoma 2 inflammasome during Streptococcus pneumoniae Infection

Infection and Immunity

Volumn 82, Issue 6, 2014, Pages 2310-2317

  Fang, Rendong ^a   Hara, Hideki ^a   Sakai, Shunsuke ^a   Hernandez Cuellar, Eduardo ^a   Mitsuyama, Masao ^a,b   Kawamura, Ikuo ^a   Tsuchiya, Kohsuke ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AIM 2 INFLAMMASOME; ALPHA INTERFERON RECEPTOR; BETA INTERFERON RECEPTOR; CRYOPYRIN; INTERFERON; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 6; MELANOMA 2 INFLAMMASOME; TUMOR PROTEIN; UNCLASSIFIED DRUG; AIM2 PROTEIN, MOUSE; CYTOKINE; DNA BINDING PROTEIN; INFLAMMASOME; NUCLEAR PROTEIN;

ARTICLE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME ACTIVATION; FEMALE; IN VIVO STUDY; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STREPTOCOCCUS PNEUMONIA; UPREGULATION; ANIMAL; C57BL MOUSE; DISEASE MODEL; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; PHYSIOLOGY; PNEUMOCOCCAL INFECTION; STREPTOCOCCUS PNEUMONIAE;

ANIMALS; CASPASE 1; CYTOKINES; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; FEMALE; IMMUNITY, INNATE; INFLAMMASOMES; INTERFERON TYPE I; INTERLEUKIN-18; MACROPHAGES; MICE; MICE, INBRED C57BL; NUCLEAR PROTEINS; PNEUMOCOCCAL INFECTIONS; SIGNAL TRANSDUCTION; STREPTOCOCCUS PNEUMONIAE;

EID: 84900401399     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01572-14     Document Type: Article

References (46)

1. Tuomanen EI, Austrian R, Masure HR. 1995. Pathogenesis of pneumococcal infection. N. Engl. J. Med. 332:1280-1284. http://dx.doi.org/10.1056/NEJM199505113321907.
2. Kadioglu A, Weiser JN, Paton JC, Andrew PW. 2008. The role of Streptococcus pneumoniae virulence factors in host respiratory colonization and disease. Nat. Rev. Microbiol. 6:288-301. http://dx.doi.org/10.1038/nrmicro1871.
3. Marriott HM, Mitchell TJ, Dockrell DH. 2008. Pneumolysin: a doubleedged sword during the host-pathogen interaction. Curr. Mol. Med. 8:497-509. http://dx.doi.org/10.2174/156652408785747924.
4. Paton JC, Rowan-Kelly B, Ferrante A. 1984. Activation of human complement by the pneumococcal toxin pneumolysin. Infect. Immun. 43: 1085-1087.
5. Houldsworth S, Andrew PW, Mitchell TJ. 1994. Pneumolysin stimulates production of tumor necrosis factor alpha and interleukin-1 beta by human mononuclear phagocytes. Infect. Immun. 62:1501-1503.
6. Malley R, Henneke P, Morse SC, Cieslewicz MJ, Lipsitch M, Thompson CM, Kurt-Jones E, Paton JC, Wessels MR, Golenbock DT. 2003. Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc. Natl. Acad. Sci. U. S. A. 100:1966-1971. http://dx.doi.org/10.1073/pnas.0435928100.
7. Shoma S, Tsuchiya K, Kawamura I, Nomura T, Hara H, Uchiyama R, Daim S, Mitsuyama M. 2008. Critical involvement of pneumolysin in production of interleukin-1alpha and caspase-1-dependent cytokines in infection with Streptococcus pneumoniae in vitro: a novel function of pneumolysin in caspase-1 activation. Infect. Immun. 76:1547-1557. http://dx.doi.org/10.1128/IAI.01269-07.
8. Kumar H, Kawai T, Akira S. 2011. Pathogen recognition by the innate immune system. Int. Rev. Immunol. 30:16-34. http://dx.doi.org/10.3109/08830185.2010.529976.
9. Opitz B, van Laak V, Eitel J, Suttorp N. 2010. Innate immune recognition in infectious and noninfectious diseases of the lung. Am. J. Respir. Crit. Care Med. 181:1294-1309. http://dx.doi.org/10.1164/rccm.200909-1427SO.
10. Albiger B, Dahlberg S, Sandgren A, Wartha F, Beiter K, Katsuragi H, Akira S, Normark S, Henriques-Normark B. 2007. Toll-like receptor 9 acts at an early stage in host defence against pneumococcal infection. Cell. Microbiol. 9:633-644. http://dx.doi.org/10.1111/j.1462-5822.2006.00814.x.
11. Koppe U, Suttorp N, Opitz B. 2012. Recognition of Streptococcus pneumoniae by the innate immune system. Cell. Microbiol. 14:460-466. http://dx.doi.org/10.1111/j.1462-5822.2011.01746.x.
12. Yoshimura A, Lien E, Ingalls RR, Tuomanen E, Dziarski R, Golenbock D. 1999. Cutting edge: recognition of Gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2. J. Immunol. 163:1-5.
13. Fernandes-Alnemri T, Yu JW, Datta P, Wu J, Alnemri ES. 2009. AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature 458:509-513. http://dx.doi.org/10.1038/nature07710.
14. Latz E. 2010. The inflammasomes: mechanisms of activation and function. Curr. Opin. Immunol. 22:28-33. http://dx.doi.org/10.1016/j.coi.2009.12.004.
15. Tsuchiya K, Hara H. 2014. The inflammasome and its regulation. Crit. Rev. Immunol. 34:41-80. http://dx.doi.org/10.1615/CritRevImmunol.2013008686.
16. Koppe U, Hogner K, Doehn JM, Muller HC, Witzenrath M, Gutbier B, Bauer S, Pribyl T, Hammerschmidt S, Lohmeyer J, Suttorp N, Herold S, Opitz B. 2012. Streptococcus pneumoniae stimulates a STING-and IFN regulatory factor 3-dependent type I IFN production in macrophages, which regulates RANTES production in macrophages, cocultured alveolar epithelial cells, and mouse lungs. J. Immunol. 188:811-817. http://dx.doi.org/10.4049/jimmunol.1004143.
17. Fang R, Tsuchiya K, Kawamura I, Shen Y, Hara H, Sakai S, Yamamoto T, Fernandes-Alnemri T, Yang R, Hernandez-Cuellar E, Dewamitta SR, Xu Y, Qu H, Alnemri ES, Mitsuyama M. 2011. Critical roles of ASC inflammasomes in caspase-1 activation and host innate resistance to Streptococcus pneumoniae infection. J. Immunol. 187:4890-4899. http://dx.doi.org/10.4049/jimmunol.1100381.
18. McNeela EA, Burke A, Neill DR, Baxter C, Fernandes VE, Ferreira D, Smeaton S, El-Rachkidy R, McLoughlin RM, Mori A, Moran B, Fitzgerald KA, Tschopp J, Pétrilli V, Andrew PW, Kadioglu A, Lavelle EC. 2010. Pneumolysin activates the NLRP3 inflammasome and promotes proinflammatory cytokines independently of TLR4. PLoS Pathog. 6:e1001191. http://dx.doi.org/10.1371/journal.ppat.1001191.
19. Witzenrath M, Pache F, Lorenz D, Koppe U, Gutbier B, Tabeling C, Reppe K, Meixenberger K, Dorhoi A, Ma J, Holmes A, Trendelenburg G, Heimesaat MM, Bereswill S, van der Linden M, Tschopp J, Mitchell TJ, Suttorp N, Opitz B. 2011. The NLRP3 inflammasome is differentially activated by pneumolysin variants and contributes to host defense in pneumococcal pneumonia. J. Immunol. 187:434-440. http://dx.doi.org/10.4049/jimmunol.1003143.
20. Parker D, Martin FJ, Soong G, Harfenist BS, Aguilar JL, Ratner AJ, Fitzgerald KA, Schindler C, Prince A. 2011. Streptococcus pneumoniae DNA initiates type I interferon signaling in the respiratory tract. mBio 2:e00016-11. http://dx.doi.org/10.1128/mBio.00016-11.
21. Davis KM, Nakamura S, Weiser JN. 2011. Nod2 sensing of lysozymedigested peptidoglycan promotes macrophage recruitment and clearance of S. pneumoniae colonization in mice. J. Clin. Invest. 121:3666-3676. http://dx.doi.org/10.1172/JCI57761.
22. Opitz B, Püschel A, Schmeck B, Hocke AC, Rosseau S, Hammerschmidt S, Schumann RR, Suttorp N, Hippenstiel S. 2004. Nucleotide-binding oligomerization domain proteins are innate immune receptors for internalized Streptococcus pneumoniae. J. Biol. Chem. 279:36426-36432. http://dx.doi.org/10.1074/jbc.M403861200.
23. González-Navajas JM, Lee J, David M, Raz E. 2012. Immunomodulatory functions of type I interferons. Nat. Rev. Immunol. 12:125-135. http://dx.doi.org/10.1038/nri3133.
24. Malireddi RK, Kanneganti TD. 2013. Role of type I interferons in inflammasome activation, cell death, and disease during microbial infection. Front. Cell. Infect. Microbiol. 3:77. http://dx.doi.org/10.3389/fcimb.2013.00077.
25. LeMessurier KS, Hacker H, Chi L, Tuomanen E, Redecke V. 2013. Type I interferon protects against pneumococcal invasive disease by inhibiting bacterial transmigration across the lung. PLoS Pathog. 9:e1003727. http://dx.doi.org/10.1371/journal.ppat.1003727.
26. Nakamura S, Davis KM, Weiser JN. 2011. Synergistic stimulation of type I interferons during influenza virus coinfection promotes Streptococcus pneumoniae colonization in mice. J. Clin. Invest. 121:3657-3665. http://dx.doi.org/10.1172/JCI57762.
27. Shahangian A, Chow EK, Tian X, Kang JR, Ghaffari A, Liu SY, Belperio JA, Cheng G, Deng JC. 2009. Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice. J. Clin. Invest. 119:1910-1920. http://dx.doi.org/10.1172/JCI35412.
28. Kafka D, Ling E, Feldman G, Benharroch D, Voronov E, Givon-Lavi N, Iwakura Y, Dagan R, Apte RN, Mizrachi-Nebenzahl Y. 2008. Contribution of IL-1 to resistance to Streptococcus pneumoniae infection. Int. Immunol. 20:1139-1146. http://dx.doi.org/10.1093/intimm/dxn071.
29. Lauw FN, Branger J, Florquin S, Speelman P, van Deventer SJ, Akira S, van der Poll T. 2002. IL-18 improves the early antimicrobial host response to pneumococcal pneumonia. J. Immunol. 168:372-378.
30. van der Poll T, Keogh CV, Guirao X, Buurman WA, Kopf M, Lowry SF. 1997. Interleukin-6 gene-deficient mice show impaired defense against pneumococcal pneumonia. J. Infect. Dis. 176:439-444. http://dx.doi.org/10.1086/514062.
31. Rijneveld AW, Florquin S, Branger J, Speelman P, Van Deventer SJ, van der Poll T. 2001. TNF-alpha compensates for the impaired host defense of IL-1 type I receptor-deficient mice during pneumococcal pneumonia. J. Immunol. 167:5240-5246.
32. Yang H, Ko HJ, Yang JY, Kim JJ, Seo SU, Park SG, Choi SS, Seong JK, Kweon MN. 2013. Interleukin-1 promotes coagulation, which is necessary for protective immunity in the lung against Streptococcus pneumoniae infection. J. Infect. Dis. 207:50-60. http://dx.doi.org/10.1093/infdis/jis651.
33. Zwijnenburg PJ, van der Poll T, Florquin S, Roord JJ, Van Furth AM. 2003. IL-1 receptor type 1 gene-deficient mice demonstrate an impaired host defense against pneumococcal meningitis. J. Immunol. 170:4724-4730.
34. Wu J, Fernandes-Alnemri T, Alnemri ES. 2010. Involvement of the AIM2, NLRC4, and NLRP3 inflammasomes in caspase-1 activation by Listeria monocytogenes. J. Clin. Immunol. 30:693-702. http://dx.doi.org/10.1007/s10875-010-9425-2.
35. Guarda G, Braun M, Staehli F, Tardivel A, Mattmann C, Forster I, Farlik M, Decker T, Du Pasquier RA, Romero P, Tschopp J. 2011. Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity 34:213-223. http://dx.doi.org/10.1016/j.immuni.2011.02.006.
36. Bauernfeind FG, Horvath G, Stutz A, Alnemri ES, MacDonald K, Speert D, Fernandes-Alnemri T, Wu J, Monks BG, Fitzgerald KA, Hornung V, Latz E. 2009. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J. Immunol. 183:787-791. http://dx.doi.org/10.4049/jimmunol.0901363.
37. Franchi L, Eigenbrod T, Nunez G. 2009. Cutting edge: TNF-alpha mediates sensitization to ATP and silica via the NLRP3 inflammasome in the absence of microbial stimulation. J. Immunol. 183:792-796. http://dx.doi.org/10.4049/jimmunol.0900173.
38. Fernandes-Alnemri T, Yu JW, Juliana C, Solorzano L, Kang S, Wu J, Datta P, McCormick M, Huang L, McDermott E, Eisenlohr L, Landel CP, Alnemri ES. 2010. The AIM2 inflammasome is critical for innate immunity to Francisella tularensis. Nat. Immunol. 11:385-393. http://dx.doi.org/10.1038/ni.1859.
39. Henry T, Brotcke A, Weiss DS, Thompson LJ, Monack DM. 2007. Type I interferon signaling is required for activation of the inflammasome during Francisella infection. J. Exp. Med. 204:987-994. http://dx.doi.org/10.1084/jem.20062665.
40. Jones JW, Kayagaki N, Broz P, Henry T, Newton K, O'Rourke K, Chan S, Dong J, Qu Y, Roose-Girma M, Dixit VM, Monack DM. 2010. Absent in melanoma 2 is required for innate immune recognition of Francisella tularensis. Proc. Natl. Acad. Sci. U. S. A. 107:9771-9776. http://dx.doi.org/10.1073/pnas.1003738107.
41. Shah S, Bohsali A, Ahlbrand SE, Srinivasan L, Rathinam VA, Vogel SN, Fitzgerald KA, Sutterwala FS, Briken V. 2013. Cutting edge: Mycobacterium tuberculosis but not nonvirulent mycobacteria inhibits IFN-beta and AIM2 inflammasome-dependent IL-1beta production via its ESX-1 secretion system. J. Immunol. 191:3514-3518. http://dx.doi.org/10.4049/jimmunol.1301331.
42. Tsuchiya K, Hara H, Kawamura I, Nomura T, Yamamoto T, Daim S, Dewamitta SR, Shen Y, Fang R, Mitsuyama M. 2010. Involvement of absent in melanoma 2 in inflammasome activation in macrophages infected with Listeria monocytogenes. J. Immunol. 185:1186-1195. http://dx.doi.org/10.4049/jimmunol.1001058.
43. Paterson GK, Blue CE, Mitchell TJ. 2005. Role of interleukin-18 in experimental infections with Streptococcus pneumoniae. J. Med. Microbiol. 54:323-326. http://dx.doi.org/10.1099/jmm.0.45873-0.
44. Hoegen T, Tremel N, Klein M, Angele B, Wagner H, Kirschning C, Pfister HW, Fontana A, Hammerschmidt S, Koedel U. 2011. The NLRP3 inflammasome contributes to brain injury in pneumococcal meningitis and is activated through ATP-dependent lysosomal cathepsin B release. J. Immunol. 187:5440-5451. http://dx.doi.org/10.4049/jimmunol.1100790.
45. Zwijnenburg PJ, van der Poll T, Florquin S, Akira S, Takeda K, Roord JJ, van Furth AM. 2003. Interleukin-18 gene-deficient mice show enhanced defense and reduced inflammation during pneumococcal meningitis. J. Neuroimmunol. 138:31-37. http://dx.doi.org/10.1016/S0165-5728(03)00088-2.
46. Mitchell AJ, Yau B, McQuillan JA, Ball HJ, Too LK, Abtin A, Hertzog P, Leib SL, Jones CA, Gerega SK, Weninger W, Hunt NH. 2012. Inflammasome-dependent IFN-gamma drives pathogenesis in Streptococcus pneumoniae meningitis. J. Immunol. 189:4970-4980. http://dx.doi.org/10.4049/jimmunol.1201687.